Alphatec Holdings, Inc. (ATEC) Shares Preliminary 2025 Results and 2026 Outlook

Core Insights - Alphatec Holdings, Inc. (NASDAQ:ATEC) is recognized as one of the top 14 booming stocks to consider for investment at present [1] Financial Performance - Preliminary total revenue for 2025 increased by 25%, expected to be between $763.4 million and $764.4 million, primarily driven by a 26% surge in surgical revenue [2] - The company reaffirmed its full-year guidance for adjusted EBITDA at $91 million and ended the year with a cash balance of $161 million [2] 2026 Outlook - For fiscal 2026, Alphatec projects revenue of $890 million, with 90% expected to be surgical-related [3] - Adjusted EBITDA is anticipated to be around $130 million, and free cash flow for the year is forecasted at approximately $20 million [3] Strategic Developments - On the same day, Alphatec announced a strategic agreement with Theradaptive, Inc. to acquire exclusive distribution rights in the U.S. for Theradaptive's rhBMP-2 solution, OsteoAdapt, enhancing its position in the procedural ecosystem [4] Market Sentiment - Wall Street has a bullish outlook on Alphatec, with a consensus Strong Buy rating and a one-year average share price target of $24.55, indicating an upside of nearly 40% as of January 12 [5]